Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
~ FDA acknowledges significant potential impact of MPAR’s oral overdose protection ~SAN DIEGO, CA / ACCESSWIRE / January 23, 2024 / Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ:ENSC), a clinical-stage company apply…